Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Eur J Intern Med. 2019 Nov;69:20-24. doi: 10.1016/j.ejim.2019.08.006. Epub 2019 Aug 12.
Although tramadol and codeine occasionally have been reported to cause hyponatremia the evidence is scarce. The objective of this investigation was to study the association between weak opioids (tramadol and codeine) and hospitalization due to hyponatremia.
This was a register-based case-control study of the general Swedish population. Those hospitalized with a principal diagnosis of hyponatremia (n = 14,359) were compared with matched controls (n = 57,383). Multivariable logistic regression adjusting for co-medication, diseases, previous hospitalizations and socioeconomic factors was used to explore the association between severe hyponatremia and the use of tramadol or codeine. Furthermore, newly initiated (≤90 days) and ongoing use was investigated separately.
Compared to controls, the unadjusted OR (95%CI) for hospitalization due to hyponatremia was 2.45 (2.26-2.66) for tramadol and 3.19 (2.92-3.47) for codeine. However, after adjustment for confounding factors the risk decreased (adjusted OR: 1.17 [1.08-1.26] and 1.14 [1.03-1.26], respectively). Newly initiated treatment with tramadol or codeine showed a significant association (adjusted OR 2.34 [95%CI 2.01-2.72] and 2.20 [95%CI 1.87-2.60], respectively). In contrast, for ongoing therapy the corresponding adjusted ORs were not elevated (adjusted OR: 0.70 [95%CI 0.61-0.80] and 1.14 [95%CI 0.99-1.30, respectively).
Associations were found between tramadol or codeine usage and hospitalization due to hyponatremia which were markedly increased in those newly initiated. The risk associated with long-term use was not increased. The association may be causally related to the drugs, although an effect due to pain, nausea or the underlying disease cannot be excluded.
曲马多和可待因偶尔会引起低钠血症,但证据不足。本研究旨在探讨弱阿片类药物(曲马多和可待因)与低钠血症住院之间的关系。
这是一项基于登记的瑞典普通人群病例对照研究。将主要诊断为低钠血症的住院患者(n=14359)与匹配的对照者(n=57383)进行比较。采用多变量逻辑回归调整合并用药、疾病、既往住院和社会经济因素,以探讨严重低钠血症与曲马多或可待因使用之间的关系。此外,还分别研究了新开始(≤90 天)和持续使用的情况。
与对照组相比,曲马多和可待因导致低钠血症住院的未经调整的比值比(95%CI)分别为 2.45(2.26-2.66)和 3.19(2.92-3.47)。然而,在调整混杂因素后,风险降低(调整后的比值比:1.17[1.08-1.26]和 1.14[1.03-1.26])。新开始使用曲马多或可待因与显著相关(调整后的比值比 2.34[95%CI 2.01-2.72]和 2.20[95%CI 1.87-2.60])。相比之下,对于持续治疗,相应的调整后比值比没有升高(调整后的比值比:0.70[95%CI 0.61-0.80]和 1.14[95%CI 0.99-1.30])。
曲马多或可待因使用与低钠血症住院相关,新开始使用时显著增加。与长期使用相关的风险没有增加。这种关联可能与药物有关,但不能排除疼痛、恶心或潜在疾病的影响。